AstraZeneca Announced TAGRISSO Plus Chemotherapy Reduced The Risk Of Disease Progression In The Brain By 42% In Patients With EGFR-Mutated Advanced Lung Cancer And Brain Metastases At Baseline
Portfolio Pulse from Charles Gross
AstraZeneca announced that its drug TAGRISSO, when combined with chemotherapy, reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases. This is based on the results from a prespecified exploratory analysis of the FLAURA2 Phase III trial. The results were presented at the European Society for Medical Oncology Congress in Madrid, Spain.
October 21, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's TAGRISSO has shown significant improvement in treating EGFR-mutated advanced lung cancer patients when combined with chemotherapy. This could potentially boost the company's revenues if the drug receives regulatory approval.
The positive results from the FLAURA2 Phase III trial for TAGRISSO could lead to increased sales for AstraZeneca if the drug receives regulatory approval. This could potentially boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100